TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 10905596
Drug: Alpha-IFN alone
Normalized name: IFN .ALPHA.-1B
DrugBank: Interferon alfa-1b (DB18522)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Alpha-IFN alone (3 MU/thrice weekly)
Study: 8935140
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of stimulant and softening laxatives
Study: 29293367
Drug: Standard subcutaneous
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard subcutaneous basal‐bolus insulin and blinded CGM (group 1)
Study: 29293367
Drug: Insulin pump
Normalized name: insulin pump syringe
Approvals — FDA: no, EMA: no, PMDA: no
Description: Insulin pump and blinded CGM (group 2)
Study: 29293367
Drug: Insulin pump
Normalized name: insulin pump syringe
Approvals — FDA: no, EMA: no, PMDA: no
Description: Insulin pump and nonblinded CGM (group 3)
Study: 29293367
Drug: All treatment
Normalized name: UNDECYLENIC ACID 8 g in 30 mL / TOLNAFTATE 1 g in 30 mL TOPICAL LIQUID [Fugal nall treatment]
Approvals — FDA: no, EMA: no, PMDA: no
Description: All treatment groups (CGM)
Study: 29293367
Drug: Group 3
Normalized name: Chlamydophila psittaci biogroup 3 Ab
Approvals — FDA: no, EMA: no, PMDA: no
Description: Group 3 (insulin pump and nonblinded CGM)
Study: 22990758
Drug: Paced breathing
Approvals — FDA: no, EMA: no, PMDA: no
Description: Paced breathing twice a day (6 breaths/minute for 15 minutes)
Study: 18656295
Drug: G-Bond (GC)
Normalized name: GCS-100
DrugBank: GCS-100 (DB17566)
Approvals — FDA: no, EMA: no, PMDA: no
Description: G-Bond (GC)
Study: 16647408
Drug: Mixing insulin
Normalized name: insulin aspart protamine, human / insulin aspart, human Injectable Suspension [NovoLog Mix]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mixing insulin glargine (IG) with a rapid‐acting insulin (RAI) analogue
Study: 14662257
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of digoxin and carvedilol
Study: 14662257
Drug: Combination therapy
Normalized name: REGN10933+REGN10987 combination therapy
DrugBank: Anti-SARS-CoV-2 REGN-COV2 (DB15691)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination therapy to carvedilol alone
Study: 8806342
Drug: 0.3 mg
Normalized name: biotin 0.3 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.3 mg sublingual nitrate tablet
Study: 8806342
Drug: 0.4 mg
Normalized name: biotin 0.4 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.4 mg sublingual nitrate spray
Study: 8806342
Drug: water +
Approvals — FDA: no, EMA: no, PMDA: no
Description: water + 0.3 mg sublingual nitrate tablet
Study: 8806342
Drug: water +
Approvals — FDA: no, EMA: no, PMDA: no
Description: water + 0.4 mg sublingual nitrate spray
Study: 31056784
Drug: Online group
Normalized name: Streptococcus viridans group
Approvals — FDA: no, EMA: no, PMDA: no
Description: Online group MBCR during chemotherapy
Study: 27084721
Drug: ombitasvir/paritaprevir/ritonavir 25/150/100
Approvals — FDA: no, EMA: no, PMDA: no
Description: ombitasvir/paritaprevir/ritonavir 25/150/100 mg once a day for 12 weeks
Study: 16988198
Drug: 2.5 mg/kg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2.5 mg/kg E2 and 22.5 mg/kg P per day (E2/P)
Study: 10775867
Drug: Mycophenolic acid
Normalized name: mycophenolic acid
DrugBank: Mycophenolic acid (DB01024)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Mycophenolic acid 1% ointment
Study: 9357096
Drug: Continuous morphine
Normalized name: morphine sulfate Oral Suspension [MST Continus]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Continuous morphine drips (10‐40 micrograms/kg.h) in pediatric patients
Study: 9357096
Drug: Acetaminophen with
Normalized name: acetaminophen with codeine ORAL ELIXIR
Approvals — FDA: no, EMA: no, PMDA: no
Description: Acetaminophen with 8 mg codeine (n = 13) or 30 mg codeine (n = 5) in adult volunteers
Study: 7691019
Drug: Post-treatment period
Normalized name: hydrocortisone
DrugBank: Hydrocortisone succinate (DB14545)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Post-treatment period (20 days)
Study: 3779500
Drug: Cimetidine 300
Normalized name: cimetidine 300 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cimetidine 300 mg + saline
Study: 3779500
Drug: Cimetidine 300
Normalized name: cimetidine 300 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cimetidine 300 mg + metoclopramide 10 mg
Study: 3779500
Drug: Ranitidine 100
Normalized name: ranitidine 100 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ranitidine 100 mg + saline
Study: 3779500
Drug: Ranitidine 100
Normalized name: ranitidine 100 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ranitidine 100 mg + metoclopramide 10 mg
Study: 28263227
Drug: Individualized physical
Normalized name: hypochlorite
DrugBank: Hypochlorite (DB11123)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Individualized physical therapy (10 sessions targeting pathoanatomical, psychosocial, and neurophysiological factors)
Study: 25901479
Drug: FPNS 1
Approvals — FDA: no, EMA: no, PMDA: no
Description: FPNS 1 × 100 μg
Study: 25901479
Drug: FPNS 2
Approvals — FDA: no, EMA: no, PMDA: no
Description: FPNS 2 × 100 μg at 4-hour intervals
Study: 25901479
Drug: FPNS 8
Approvals — FDA: no, EMA: no, PMDA: no
Description: FPNS 8 × 100 μg consecutively
Study: 23719682
Drug: Hydrocodone bitartrate
Normalized name: Hydrocodone Bitartrate
DrugBank: Ibuprofen (DB01050)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Hydrocodone bitartrate ER capsules
Study: 9876334
Drug: Terbutaline (3x5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Terbutaline (3x5 mg/day p.o.)
Study: 9876334
Drug: Ketotifen (2x1
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ketotifen (2x1 mg/day p.o. for three weeks)
Study: 2244710
Drug: Nebulized atropine
Normalized name: Atropine
DrugBank: Atropine (DB00572)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Nebulized atropine methylnitrate (AMN) + albuterol (ALB)
Study: 31129917
Drug: Pharmacy care
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pharmacy care (medication review, regular dose dispensing, and counselling)
Study: 28818994
Drug: Diacerein 100
Approvals — FDA: no, EMA: no, PMDA: no
Description: Diacerein 100 mg/day
Study: 25938990
Drug: Low-molecular-weight heparin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low-molecular-weight heparin (LMWH) with vitamins and 5000 IU of dalteparin-sodium for up to 24 weeks' gestation
Study: 25938990
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group received multivitamin pills
Study: 24121976
Drug: Letrozole 2.5
Normalized name: letrozole 2.5 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Letrozole 2.5 mg per day for 6 months (Group 1)
Study: 19464613
Drug: Dexmedetomidine (1.0
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dexmedetomidine (1.0 microg/kg for 10 min, followed by 0.7 microg x kg(‐1) x hr(‐1) continuous infusion)
Study: 19464613
Drug: Placebo (ESC
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (ESC of fentanyl = 2 ng/mL)
Study: 19464613
Drug: Placebo (ESC
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (ESC of fentanyl = 4 ng/mL)
Study: 16681478
Drug: Sildenafil (25,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sildenafil (25, 50, 100 mg, as needed)
Study: 14872172
Drug: PncDT11 vaccine
Normalized name: Pertussis vaccine
DrugBank: Pertussis vaccine (DB15274)
Approvals — FDA: no, EMA: no, PMDA: no
Description: PncDT11 vaccine
Study: 11566639
Drug: 20 mg
Normalized name: urea 20 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 20 mg PEG-OB protein/wk for 12 weeks
Study: 8154486
Drug: Dietary protein
Normalized name: protein C
DrugBank: Protein C (DB11312)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dietary protein intake of 1.3 g/kg body weight/d
Study: 8154486
Drug: Dietary protein
Normalized name: protein C
DrugBank: Protein C (DB11312)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dietary protein intake of 0.575 g/kg body weight/d
Study: 8154486
Drug: Dietary protein
Normalized name: protein C
DrugBank: Protein C (DB11312)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dietary protein intake of 0.28 g/kg body weight/d (supplemented with amino acids or their keto analogs)
Study: 1137255
Drug: 15 mg
Normalized name: papain 15 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 15 mg of prednisone every 8 hours (Group A)
Study: 1137255
Drug: 45 mg
Normalized name: lutein 45 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 45 mg of prednisone every morning (Group B)
Study: 1137255
Drug: 90 mg
Normalized name: papain 90 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 90 mg of prednisone every other morning (Group C)
Study: 31184941
Drug: Conventional intraligamentary
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conventional intraligamentary injection
Study: 28200017
Drug: Tailored preventive
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tailored preventive oral health intervention
Study: 26317978
Drug: COBAS Amplicor
Approvals — FDA: no, EMA: no, PMDA: no
Description: COBAS Amplicor V2, Roche (CA) (lower detection limit 50 IU/ml)
Study: 26317978
Drug: VERSANT HCV-RNA
Approvals — FDA: no, EMA: no, PMDA: no
Description: VERSANT HCV-RNA Qualitative Assay, Siemens (TMA) (lower limit detection 10 IU/ml)
Study: 26317978
Drug: TMA undetectable
Approvals — FDA: no, EMA: no, PMDA: no
Description: TMA undetectable patients (14 weeks treatment)
Study: 26317978
Drug: TMA positive
Normalized name: salicylic acid
DrugBank: Salicylic acid (DB00936)
Approvals — FDA: no, EMA: no, PMDA: no
Description: TMA positive patients (14 weeks treatment)
Study: 26317978
Drug: Both CA
Normalized name: Bothrops atrox venom
Approvals — FDA: no, EMA: no, PMDA: no
Description: Both CA and TMA undetectable (genotype 2, 14 weeks treatment)
Study: 20187348
Drug: Cetirizine hydrochloride
Normalized name: Cetirizine Hydrochloride
DrugBank: Cetirizine (DB00341)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Cetirizine hydrochloride (Zyrtec, 10 mg)
Study: 11802244
Drug: CPX (8‐cyclopentyl‐1,3‐dipropylxanthine)
Normalized name: 5-Ethyl-8-oxo-5,8-dihydro-1,3-dioxa-5,6-diaza-cyclopenta[b]naphthalene-7-carboxylic acid
DrugBank: DPCPX (DB12946)
Approvals — FDA: no, EMA: no, PMDA: no
Description: CPX (8‐cyclopentyl‐1,3‐dipropylxanthine) at doses of 1, 3, 10, 30, 100, 300, and 1,000 mg
Study: 7747622
Drug: Cumulative intake
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cumulative intake of aluminum gels
Study: 2245928
Drug: ASA (Aspirin)
Normalized name: Aspirin
DrugBank: Acetylsalicylic acid (DB00945)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: ASA (Aspirin)
Study: 6455734
Drug: Physical training
Approvals — FDA: no, EMA: no, PMDA: no
Description: Physical training (conditioning exercises twice a week for eight weeks)
Study: 26489804
Drug: Simvastatin 40
Normalized name: simvastatin 40 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Simvastatin 40 mg and Ezetimibe 10 mg daily
Study: 23128915
Drug: Transforaminal (TF)
Normalized name: transforming growth factor beta 2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Transforaminal (TF) epidural steroid injection (ESI)
Study: 23128915
Drug: Interlaminar (IL)
Normalized name: Ile
DrugBank: Isoleucine (DB00167)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Interlaminar (IL) epidural steroid injection (ESI)
Study: 21845341
Drug: Strength Training
Approvals — FDA: no, EMA: no, PMDA: no
Description: Strength Training (ST, N = 13, twice a week, 70‐90% 1‐RM)
Study: 21845341
Drug: Power Training
Approvals — FDA: no, EMA: no, PMDA: no
Description: Power Training (PT, N = 15, twice a week, 30‐50% 1‐RM)
Study: 8894937
Drug: d-sotalol (2
Approvals — FDA: no, EMA: no, PMDA: no
Description: d-sotalol (2 mg/kg IV in 15 min, followed by 1 mg/kg per hour)
Study: 6152120
Drug: Fansidar (1
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fansidar (1 tablet a week)
Study: 29059120
Drug: Daily Engagement
Approvals — FDA: no, EMA: no, PMDA: no
Description: Daily Engagement in Meaningful Activity (DEMA)
Study: 25461390
Drug: Supplemental vitamin
Normalized name: Vitamin A
DrugBank: Vitamin A (DB00162)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Supplemental vitamin D (4000 IU and 8000 IU) in vitamin D insufficient subjects (serum 25(OH)D<29 ng/mL)
Study: 22971719
Drug: Two types
Approvals — FDA: no, EMA: no, PMDA: no
Description: Two types of antiplatelet agents (Group I)
Study: 22971719
Drug: Single antiplatelet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single antiplatelet agent plus warfarin (Group II)
Study: 21480316
Drug: Long-term low-dose
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Long-term low-dose peginterferon therapy
Study: 21480316
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (no peginterferon therapy)
Study: 19657203
Drug: Therapeutic touch
Normalized name: Moisturel Therapeutic
Approvals — FDA: no, EMA: no, PMDA: no
Description: Therapeutic touch (contact on neck and shoulders, delivered twice daily for 3 days)
Study: 19657203
Drug: Placebo treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo treatment (mimic treatment identical in appearance)
Study: 16445337
Drug: SW and
Normalized name: cytarabine and daunorubicin
Approvals — FDA: no, EMA: no, PMDA: no
Description: SW and nonsteroidal anti-inflammatory drugs
Study: 30719273
Drug: Antithyroid drugs
Approvals — FDA: no, EMA: no, PMDA: no
Description: Antithyroid drugs
Study: 15789920
Drug: Antithyroid drugs
Approvals — FDA: no, EMA: no, PMDA: no
Description: Antithyroid drugs + Azathioprine
Study: 23884073
Drug: Standard treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard treatment (pegylated interferon alfa‐2a and ribavirin therapy) without psychoeducation
Study: 10791186
Drug: Omeprazole 20
Normalized name: omeprazole 20 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Omeprazole 20 mg i.v.
Study: 10791186
Drug: Saline 2
Normalized name: SODIUM CHLORIDE BRONCHO-SALINE 240ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: Saline 2 cc i.v. (Control)
Study: 9715298
Drug: Intrathecal pethidine
Normalized name: pethidine
DrugBank: Meperidine (DB00454)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intrathecal pethidine 5% (50 mg/ml) 0.5 mg/kg
Study: 9715298
Drug: 5% lignocaine
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5% lignocaine 1 ml
Study: 1864086
Drug: Topical prednisolone
Normalized name: prednisolone Topical Cream
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical prednisolone eye drops (tapering dosage)
Study: 6824996
Drug: Prostaglandin E2
Normalized name: Prostaglandin E2
DrugBank: Dinoprostone (DB00917)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Prostaglandin E2 (PGE2) at doses of 0.1 mg, 0.5 mg, and 1.0 mg
Study: 17945530
Drug: Aliskiren (300
Approvals — FDA: no, EMA: no, PMDA: no
Description: Aliskiren (300 mg qd)
Study: 17945530
Drug: Ramipril (10
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ramipril (10 mg qd)
Study: 16230121
Drug: Subcutaneous low-dose
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Subcutaneous low-dose heparin (3 x 5000 IU/day for 2 days, then 2 x 5000 IU/day for 12 days, maintenance 5000 IU/day)
Study: 16230121
Drug: Oral pentosan
Normalized name: Pentosan polysulfate
DrugBank: Pentosan polysulfate (DB00686)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oral pentosan polysulfate (PPS) alone
Study: 16230121
Drug: Subcutaneous low-dose
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Subcutaneous low-dose heparin and oral PPS
Study: 11850096
Drug: Insulin treatment
Normalized name: INSULIN
DrugBank: Insulin beef (DB09456)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Insulin treatment for 12 weeks
Study: 11850096
Drug: Oral agents
Normalized name: DENTAL AND ORAL AGENTS,TOPICAL
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral agents (comparison group)
Study: 7625338
Drug: Low fat
Normalized name: Low fat spread
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low fat diet (LF) - 20% of energy as fat, 67% as carbohydrate, 13% as protein; 4.80 kJ/g
Study: 7625338
Drug: Medium fat
Normalized name: Hard fat
DrugBank: Hard fat (DB11578)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Medium fat diet (MF) - 40% of energy as fat, 47% as carbohydrate, 13% as protein; 5.59 kJ/g
Study: 7625338
Drug: High fat
Normalized name: Hard fat
DrugBank: Hard fat (DB11578)
Approvals — FDA: no, EMA: no, PMDA: no
Description: High fat diet (HF) - 60% of energy as fat, 27% as carbohydrate, 13% as protein; 7.04 kJ/g
Study: 2199131
Drug: 20 mg
Normalized name: urea 20 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 20 mg (+/‐)‐nicardipine
Study: 150813
Drug: Zinc sulfate
Normalized name: Zinc Sulfate
DrugBank: Zinc acetate (DB14487)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Zinc sulfate monohydrate, 411 mg total daily dosage
Study: 29242413
Drug: Daily assisted
Approvals — FDA: no, EMA: no, PMDA: no
Description: Daily assisted physical exercise (one session daily starting from one week of postnatal age, including range-of-motion exercises with gentle compression, flexion and extension of all extremities for 10-15 min)
Study: 26125277
Drug: Sertraline (n=60)
DrugBank: Sertraline (DB01104)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Sertraline (n=60)
Study: 23102845
Drug: 100 mg
Normalized name: urea 100 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 100 mg FSH im once a day for 4 days (N = 5)
Study: 23102845
Drug: 200 mg
Normalized name: RNA 200 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 200 mg FSH sc on Day 3 and Day 5 (N = 4)
Study: 23102845
Drug: 200 mg
Normalized name: RNA 200 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 200 mg FSH plus 2.5 mg LH sc on Day 3 and Day 5 (N = 4)
Study: 16501860
Drug: Low-dose gemcitabine
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Low-dose gemcitabine infusion (250 mg/m2)
Study: 16501860
Drug: Standard-dose gemcitabine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard-dose gemcitabine infusion (1000 mg/m2)
Study: 12928902
Drug: Acyclovir 200
Normalized name: acyclovir 200 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Acyclovir 200 mg five times/day for 3 weeks (Group A)
Study: 12928902
Drug: Acyclovir 200
Normalized name: acyclovir 200 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Acyclovir 200 mg five times/day for 1 year (Group B)
Study: 12928902
Drug: Acyclovir 200
Normalized name: acyclovir 200 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Acyclovir 200 mg five times/day in combination with MMF 1 g twice daily for 1 year (Group C)
Study: 11164664
Drug: Growth hormone
Normalized name: Growth hormone
DrugBank: Somatotropin (DB00052)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Growth hormone (GH) 0.1 mg/kg injected subcutaneously three times a week
Study: 11164664
Drug: Isotonic saline
Approvals — FDA: no, EMA: no, PMDA: no
Description: Isotonic saline solution injected at the same times as GH
Study: 9217519
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of lorazepam and haloperidol
Study: 2823840
Drug: 1500 aPTT‐U
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1500 aPTT‐U low molecular weight heparin plus 0.5 mg dihydroergotamine (HNMD; Embolex NM)
Study: 2823840
Drug: 5000 IU
Normalized name: D 5000 IU
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5000 IU of the heparin‐dihydroergotamine combination Heparin‐Dihydergot (twice daily)
Study: 49984
Drug: Chemotherapy (Hydroxyurea)
Normalized name: menthol
DrugBank: Menthol (DB14123)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chemotherapy (Hydroxyurea) only
Study: 30983166
Drug: Atorvastatin 40mg
Normalized name: AMLODIPINE 5MG/ATORVASTATIN 40MG TAB
DrugBank: Atorvastatin (DB01076)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Atorvastatin 40mg daily
Study: 28902426
Drug: Surgical therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Surgical therapy aiming at pocket elimination with systemic antibiotics
Study: 28902426
Drug: Surgical therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Surgical therapy aiming at pocket elimination with antiseptic agent for implant surface decontamination
Study: 28902426
Drug: Surgical therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Surgical therapy aiming at pocket elimination with both systemic antibiotics and antiseptic agent
Study: 28902426
Drug: Surgical therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Surgical therapy aiming at pocket elimination (control group)
Study: 21366634
Drug: H. pylori
Normalized name: H. PYLORI AGENTS
Approvals — FDA: no, EMA: no, PMDA: no
Description: H. pylori eradication therapy (ranitidine bismuth citrate 400 mg and clarithromycin 500 mg twice daily for 2 weeks)
Study: 12970274
Drug: GH at
Normalized name: rose bengal AT
Approvals — FDA: no, EMA: no, PMDA: no
Description: GH at 25.0 microg/kg x day (pediatric dose)
Study: 12970274
Drug: GH at
Normalized name: rose bengal AT
Approvals — FDA: no, EMA: no, PMDA: no
Description: GH at 12.5 microg/kg x day (adult dose)
Study: 12970274
Drug: No GH
Approvals — FDA: no, EMA: no, PMDA: no
Description: No GH treatment (control)
Study: 10784079
Drug: Full-day treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Full-day treatment classroom only
Study: 10784079
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of parent training with classroom treatment
Study: 8678501
Drug: Continuous intravenous
Normalized name: Ivy Dry Super Continuous Spray
Approvals — FDA: no, EMA: no, PMDA: no
Description: Continuous intravenous infusion of azasetron (2.5 mg bolus followed by 7.5 mg continuous infusion for 24 hrs)
Study: 8678501
Drug: Continuous intravenous
Normalized name: Ivy Dry Super Continuous Spray
Approvals — FDA: no, EMA: no, PMDA: no
Description: Continuous intravenous infusion of azasetron
Study: 8678501
Drug: Bolus intravenous
Normalized name: SET,INFUSION,BOLUS
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bolus intravenous injection of azasetron (10 mg)
Study: 2059393
Drug: Enalapril 20
Normalized name: enalapril 20 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Enalapril 20 mg/day for 8 weeks
Study: 2059393
Drug: Nitrendipine 20
Normalized name: nitrendipine 20 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nitrendipine 20 to 40 mg/day for 8 weeks (after enalapril)
Study: 28335701
Drug: Whole-body vibration
Normalized name: Insects (whole body), mite dermatophagoides farinae
Approvals — FDA: no, EMA: no, PMDA: no
Description: Whole-body vibration therapy (VG)
Study: 28335701
Drug: Conventional physical
Normalized name: hypochlorite
DrugBank: Hypochlorite (DB11123)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conventional physical therapy (CG)
Study: 26043560
Drug: Tiaogan Lipi
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tiaogan Lipi Recipe (TLR), one dose per day for 12 weeks
Study: 26043560
Drug: Placebo, one
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo, one dose per day for 12 weeks
Study: 21593661
Drug: Raltegravir (RAL)
DrugBank: Raltegravir (DB06817)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Raltegravir (RAL) 400 mg twice daily